Lion TCR

Focus: Lion TCR is a Singapore-based biotech company founded in 2021 specializing in T cell receptor (TCR) redirected T cell therapies for oncology and viral diseases. The company is at an early stage with a focused pipeline targeting hepatocellular carcinoma and chronic hepatitis B.

Gene Therapy Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Lion TCR

AI assessmentNot Hiring

No open roles listed right now. Follow Lion TCR to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

9 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

LioCyx-M, HBV antigen-specific TCR-redirected T cells

Hepatocellular Carcinoma

Phase 1

Clinical Trials (1)

NCT06961617Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma

Phase 1

Help build intelligence for Lion TCR

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a well-focused biotech with differentiated TCR platform technology in high-unmet-need oncology indications
Portfolio concentrated in hepatocellular carcinoma where TCR-T approaches offer potential advantages over CAR-T in solid tumors
Singapore headquarters provides access to Asian biotech innovation ecosystem and emerging markets with high HCC burden

Watch Out For

Very early-stage pipeline with only 1 Phase 2 program (LioCyx-M); majority of programs remain Phase 1 with uncertain clinical validation
No disclosed funding, revenue, or employee headcount data—suggests limited transparency or undercapitalization risk
Currently zero open job positions listed, indicating either organizational contraction, hiring freeze, or nascent growth stage

Generated by Claude from Lion TCR's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Biological: TCR-T

Recurrent Hepatocellular Carcinoma

Phase 1

Clinical Trials (1)

NCT02719782A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation

Phase 1

TCR redirected T cells

Hepatocellular Carcinoma

Phase 1

Clinical Trials (1)

NCT03899415TCR-Redirected T Cells Therapy in Patient With HBV Related HCC

Phase 1